CD82 and prostate carcinoma: In addition, analysis of the survival curves in the present study revealed that the expression of KAI1 was positively associated with the survival of patients, which is consistent with the conclusions from studies performed on malignant melanoma (11), non-small-cell lung cancer (13) and prostate cancer (14).